DHR Q3 Earnings Beat on Biotechnology Strength, Sales in Line
Danaher's third-quarter earnings beat estimates by 9.9%, driven by stronger Biotechnology profitability, while it raised its 2026 adjusted earnings outlook.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo